Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.68 |
| ▸ | NQO1 | P15559 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92159 | 0.93 | NQO1 (0.78) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27799297 | 0.90 | NQO1 (0.74) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| SCHEMBL12476726 | 0.90 | NQO1 (0.82) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| SCHEMBL6285912 | 0.90 | NQO1 (0.82) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| SCHEMBL12736285 | 0.86 | NQO1 (0.67) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| Cyanide SCHEMBL28150915 | 0.86 | NQO1 (0.67) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| SCHEMBL2492122 | 0.86 | NQO1 (0.67) | LTA4HNQO1TDP1TSHRALDH1A1 | |
| Phenetole SCHEMBL28299913 | 0.85 | LTA4H (0.72) | LTA4HNQO1ALDH1A1MAPTMEN1 | |
| SCHEMBL8736875 | 0.84 | LTA4H (0.60) | LTA4HNQO1TDP1ALDH1A1MAPT | |
| SCHEMBL1688856 | 0.83 | TEAD4 (0.56) | LTA4HTDP1TEAD4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271998-B2 | Method of inhibiting nonsense-mediated mRNA decay | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140206637-A1 | Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140073685-A1 | METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073685-A1 | METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY | EIF5B, RNMT, SARM1 | LTA4H 2306/4885NQO1 33/4885TDP1 605/4885 |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | LTA4H 1342/4885NQO1 1264/4885TDP1 1729/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | LTA4H 1342/4885NQO1 1264/4885TDP1 1729/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | LTA4H 4145/4885NQO1 2043/4885TDP1 2205/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | LTA4H 208/4885NQO1 2719/4885TDP1 3275/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | LTA4H 179/4885NQO1 3499/4885TDP1 2902/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | LTA4H 4145/4885NQO1 2043/4885TDP1 2205/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | LTA4H 208/4885NQO1 2719/4885TDP1 3275/4885 |
| US-20140206637-A1 | Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A | EIF5B, UPF1, NUDT21 | LTA4H 1953/4885NQO1 83/4885TDP1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.